Effectiveness of infliximab after adalimumab failure in Crohn's disease

Table 1 Characteristics of study patients n (%)

Gender (female %)	10 (67)
Median age (yr)	33
Time of evolution to adalimumab therapy (mo)	69
Location
L1	7 (47)
L2	1 (6)
L3	7 (47)
Behavior (%)
Inflammatory	10 (67)
Stricturing	4 (27)
Fistulizing	1 (6)
Perianal disease	4 (27)
Smoking habit	3 (21)
Previous surgical resection	7 (47)
Concomitant immunosuppressants	11 (71)
Reason for discontinuation of adalimumab
Partial response	7 (47)
Loss of efficacy	5 (33)
Adverse events	3 (20)

L1: Ileum; L2: Colon; L3: Ileum and colon.

Table 2 Responses to the switch from adalimumab to infliximab

Reason for ADA discontinuation	Indication for anti-TNF	Initial response to ADA	Final response to ADA	ADA escalation	Initial response to ADA escalation	Final response to ADA escalation	Initial response to IFX	AE with IFX
Loss of response	Perianal	Partial response	No response	No	NA	NA	Remission	No
Loss of response	Luminal	Remission	No response	No	NA	NA	Remission	No
Loss of response	Luminal	Partial response	No response	Yes	Partial response	No response	Remission	No
Loss of response	Luminal	Partial response	Partial response	Yes	No response	NA	Partial response	No
Loss of response	Luminal	Partial response	No response	Yes	No response	NA	Partial response	No
Partial response	Luminal	Partial response	Partial response	No	NA	NA	Partial response	No
Partial response	Perianal	Partial response	No response	Yes	Partial response	Partial response	Partial response	No
Partial response	Luminal	Partial response	Partial response	No	NA	NA	Partial response	No
Partial response	Luminal	Partial response	Partial response	No	NA	NA	Partial response	No
Partial response	Luminal	Partial response	Partial response	Yes	Partial response	Partial response	No response	No
Partial response	Luminal	Partial response	Partial response	Yes	Partial response	Partial response	No response	No
Partial response	Perianal	Partial response	Partial response	No	NA	NA	Partial response	No
Adverse events	Luminal	Remission	Remission	No	NA	NA	Remission	No
Adverse events	Perianal	Partial response	Partial response	No	NA	NA	Partial response	Yes
Adverse events	Luminal	Remission	Remission	No	NA	NA	Remission	Yes

ADA: Adalimumab; TNF: Tumour necrosis factor; IFX: Infliximab; NA: Not applicable; AE: Adverse events.